This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Roger, T. Articles by Calandra, T. Search for Related Content PubMed PubMed Citation Articles by Roger, T. Articles by Calandra, T. Social Bookmarking                         What's this?

Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria

Department of Internal Medicine, Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Michel P. Glauser

Department of Internal Medicine, Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Thierry Calandra

Department of Internal Medicine, Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, thierry.calandra{at}chuv.hospvd.ch

Discovered in the early 1960s as a T-cell cytokine, MIF has emerged to be an important mediator of the innate immune system. MIF was identified recently to be released by a vast array of cells, including monocytes/macrophages, T-cells, B-cells, endocrine cells and epithelial cells in response to infection and stress. Bacteria, microbial toxins and cytokines have been shown to be powerful inducers of MIF secretion by macrophages. MIF stimulates the expression of pro-inflammatory mediators by immune cells and functions to counterbalance the anti-inflammatory and immunosuppressive effects of glucocorticoids. Like TNF and IL-1, MIF plays an important role in host responses to infection. Recombinant MIF was found to exacerbate lethal endotoxemia or bacterial sepsis when co-injected with LPS or Escherichia coli in mice. Conversely, MIF knockout mice or mice treated with anti-MIF antibodies were protected from shock induced by LPS, staphylococcal exotoxins or bacterial peritonitis, even when anti-MIF therapy was started after the onset of infection. Given the central role played by MIF in innate immune responses against microbial pathogens and in the regulation of inflammatory responses, pharmacological modulation of MIF production or neutralization of MIF activity could have broad clinical applications and may offer new treatment options for the management of patients with severe sepsis or septic shock.

Journal of Endotoxin Research, Vol. 7, No. 6, 456-460 (2001)
DOI: 10.1177/09680519010070061101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?